CDKN2B and Ewing sarcoma: Therefore, it is necessary to measure biomarkers such as universal secondary mutations (e.g., TP53, STAG2, IGF2BP3 and the CDKN2A/CDKN2B status in Ewing sarcoma patients) [101]; IGF1 and IGF2 ligand levels and IGF1R, IR and IRA receptor expression in select patients who may benefit from treatment with IGF1R inhibitors.